Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.31
+7.36 (3.66%)
AAPL  253.79
+7.16 (2.90%)
AMD  203.43
+7.39 (3.77%)
BAC  48.75
+1.52 (3.22%)
GOOG  286.90
+13.76 (5.04%)
META  572.13
+35.75 (6.67%)
MSFT  370.17
+11.21 (3.12%)
NVDA  174.44
+9.28 (5.62%)
ORCL  147.11
+8.31 (5.99%)
TSLA  371.56
+16.28 (4.58%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.